Nectar Lifesciences is currently trading at Rs. 20.50, up by 0.05 points or 0.24% from its previous closing of Rs. 20.45 on the BSE.
The scrip opened at Rs. 20.40 and has touched a high and low of Rs. 21.85 and Rs. 19.95 respectively. So far 59435 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 27.40 on 02-Jun-2011 and a 52 week low of Rs. 15.05 on 09-Jan-2012.
Last one week high and low of the scrip stood at Rs. 21.85 and Rs. 19.10 respectively. The current market cap of the company is Rs. 473.19 crore.
The promoters holding in the company stood at 44.35% while Institutions and Non-Institutions held 15.58% and 19.55% respectively.
Nectar Lifesciences, a leading integrated pharmaceutical organization, has been granted ‘Certificate of Suitability’ for its key sterile molecule Cefuroxime Sodium in European Union (EU). The company already has EU cGMP approval for Cefuroxime Sodium, which was granted in October, 2011.
Cefuroxime Sodium is marketed by Innovator GSK as ZINACEF TM in EU and US as injectable is a $500 million molecule globally, of which, European sales constitute approximately 35% ($175 million). This translates into a significant opportunity for the company as indisputably one of the largest global player in cephalosporins which includes Cefuroxime Sodium in terms of production capacity for APIs.
The company already has developed formulations for Cefuroxime injections (750 mg and 7.5 g) and has already filed ANDA for US and will very soon file MAA in EU in current financial year.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1768.75 |
Dr. Reddys Lab | 1337.30 |
Cipla | 1448.00 |
Lupin | 2155.25 |
Zydus Lifesciences | 1000.80 |
View more.. |